Marker Therapeutics (MRKR) EBITDA Margin (2016 - 2025)
Marker Therapeutics (MRKR) posted quarterly EBITDA Margin of 170.74% for Q4 2025, up 75.0% year-over-year from 97.56% in Q4 2024, and up 1.48% quarter-over-quarter from 173.3% in Q3 2025.
Marker Therapeutics (MRKR) EBITDA Margin (2016 - 2025) Analysis & Trends
Marker Therapeutics (MRKR) has reported EBITDA Margin for 9 consecutive years, with 170.74% the latest figure, recorded in Q4 2025.
- In Q4 2025, EBITDA Margin rose 75.0% year-over-year to 170.74%; the TTM figure through Dec 2025 stood at 373.29% (down 22349.0% YoY), while the FY2025 annual figure was 363.45%, down 19476.0% from the prior year.
- EBITDA Margin grew to 170.74% in Q4 2025 per MRKR's latest filing, from 173.3% in the prior quarter.
- Across five years, EBITDA Margin topped out at 821.87% in Q2 2023 and bottomed at 1420.14% in Q1 2025.
- Historically, EBITDA Margin has averaged 408.9% across 4 years, with a median of 204.89% in 2024.
- Annual changes were most pronounced in 2023 — EBITDA Margin soared 148835 bps — and 2025, when it slumped 121525 bps.
- Marker Therapeutics' EBITDA Margin stood at 400.28% in 2022, then plunged by 210 bps to 1242.22% in 2023, then soared by 86 bps to 171.48% in 2024, then grew by 0 bps to 170.74% in 2025.
- Business Quant data shows MRKR's EBITDA Margin at 170.74% in Q4 2025, 173.3% in Q3 2025, and 494.79% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Marker Therapeutics | 23.95 Mn | 12.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -170.74% |
| Sep 30, 2025 | -173.30% |
| Jun 30, 2025 | -494.79% |
| Mar 31, 2025 | -1,420.14% |
| Dec 31, 2024 | -171.48% |
| Sep 30, 2024 | -124.60% |
| Jun 30, 2024 | -115.40% |
| Mar 31, 2024 | -204.89% |
| Sep 30, 2023 | -1,242.22% |
| Jun 30, 2023 | 821.87% |
| Mar 31, 2023 | -172.38% |
| Dec 31, 2022 | -400.28% |
| Sep 30, 2022 | -582.90% |
| Jun 30, 2022 | -666.47% |
| Mar 31, 2022 | -1,015.71% |
| Dec 31, 2020 | -25,616.37% |
| Jun 30, 2020 | -1,361.99% |
| Dec 31, 2019 | -2,681.02% |
| Jun 30, 2018 | -2,268.90% |
| Sep 30, 2017 | -2,179.30% |